Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) EBITDA Margin (2020 - 2022)

RAPT Therapeutics (RAPT) has disclosed EBITDA Margin for 3 consecutive years, with 2123.25% as the latest value for Q2 2022.

  • Quarterly EBITDA Margin fell 27538.0% to 2123.25% in Q2 2022 from the year-ago period, while the trailing twelve-month figure was 10291.76% through Mar 2023, down 799950.0% year-over-year, with the annual reading at 5478.59% for FY2022, 366288.0% down from the prior year.
  • EBITDA Margin hit 2123.25% in Q2 2022 for RAPT Therapeutics, up from 3335.26% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 956.7% in Q2 2020 to a low of 3335.26% in Q1 2022.
  • Historically, EBITDA Margin has averaged 1730.04% across 3 years, with a median of 1627.25% in 2020.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 5426bps in 2021 and later crashed -198288bps in 2022.
  • Year by year, EBITDA Margin stood at 997.39% in 2020, then crashed by -141bps to 2404.76% in 2021, then grew by 12bps to 2123.25% in 2022.
  • Business Quant data shows EBITDA Margin for RAPT at 2123.25% in Q2 2022, 3335.26% in Q1 2022, and 2404.76% in Q4 2021.